Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Gross Margin (2016 - 2025)

Historic Gross Margin for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to 88.49%.

  • Amicus Therapeutics' Gross Margin fell 21300.0% to 88.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.77%, marking a year-over-year decrease of 2100.0%. This contributed to the annual value of 89.98% for FY2024, which is 6700.0% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Gross Margin is 88.49%, which was down 21300.0% from 90.16% recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Gross Margin peaked at 91.95% during Q1 2023, and registered a low of 83.55% during Q3 2022.
  • For the 5-year period, Amicus Therapeutics' Gross Margin averaged around 89.47%, with its median value being 90.16% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 68400bps in 2023, then tumbled by -42400bps in 2024.
  • Over the past 5 years, Amicus Therapeutics' Gross Margin (Quarter) stood at 90.44% in 2021, then dropped by -1bps to 89.35% in 2022, then increased by 1bps to 90.16% in 2023, then decreased by 0bps to 90.09% in 2024, then decreased by -2bps to 88.49% in 2025.
  • Its last three reported values are 88.49% in Q3 2025, 90.16% for Q2 2025, and 90.66% during Q1 2025.